RXST financial statements and SEC filings
RXST annual income statement
| Fiscal period end | Revenue | Operating income | Net income | SEC filing |
|---|
| 2025-12-31 | $134.48M | -$48.19M | -$38.94M | 10-K |
| 2024-12-31 | $139.93M | -$36.86M | -$27.45M | 10-K |
| 2023-12-31 | $89.08M | -$50.09M | -$48.61M | 10-K |
| 2022-12-31 | $49.01M | -$63.32M | -$66.76M | 10-K |
| 2021-12-31 | $22.59M | -$52.79M | -$48.69M | 10-K |
| 2020-12-31 | $14.68M | -$35.41M | $3.37M | 10-K |
RXST annual balance sheet
| Fiscal period end | Assets | Liabilities | Equity | SEC filing |
|---|
| 2025-12-31 | $311.81M | $36.13M | $275.68M | 10-Q |
| 2024-12-31 | $318.56M | $37.33M | $281.24M | 10-K |
| 2023-12-31 | $182.55M | $22.19M | $160.36M | 10-K |
| 2022-12-31 | $150.16M | $60.26M | $89.90M | 10-K |
| 2021-12-31 | $192.72M | $54.48M | $138.24M | 10-K |
| 2020-12-31 | $100.68M | $44.91M | -$430.59M | 10-K |
RXST annual cash flow
| Fiscal period end | Operating cash flow | Capital expenditure | Financing cash flow | SEC filing |
|---|
| 2025-12-31 | -$15.51M | -$3.83M | $1.86M | 10-K |
| 2024-12-31 | -$16.95M | -$5.44M | $123.32M | 10-K |
| 2023-12-31 | -$41.59M | -$4.81M | $61.52M | 10-K |
| 2022-12-31 | -$58.85M | -$2.39M | $6.33M | 10-K |
| 2021-12-31 | -$44.71M | -$1.94M | $137.34M | 10-K |
| 2020-12-31 | -$35.20M | -$2.54M | $25.24M | 10-K |